Moderna, Inc. (MRNA)
Moderna Stock Climbs on Flu Vaccine Approval
Moderna Inc (NASDAQ:MRNA) is up 3.6% at $58.30 ahead of the open, after the U.S. Food and Drug Administration (FDA) approved the company's mRNA-based seasonal flu vaccine , mFluvis, for adults ages 50 and older.
FDA Approves First mRNA Flu Vaccine For Older Adults
"Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America's seniors. This approval also reflects the ongoing potential of our mRNA platform,” Moderna CEO Stéphane Bancel said.
The Food and Drug Administration approved Moderna's mRNA flu vaccine, the first of its kind, capping a review that nearly collapsed in February.
The decision caps a seven-month review that included a rare refusal to consider the shot at all.
US FDA approves first mRNA flu shot from Moderna
The U.S. Food and Drug Administration has approved Moderna's flu vaccine for people aged 50 and older, the company said on Wednesday, marking the first approval of a messenger RNA-based vaccine for seasonal flu.
Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine
Moderna's vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.
MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback
Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.
Moderna, Inc. (MRNA) Q2 2026 Earnings Call Transcript
Moderna, Inc. (MRNA) Q2 2026 Earnings Call Transcript
Moderna Q2: Weak Revenue, Strong Pipeline - Here's What Matters Now
Moderna is navigating a post-COVID transition, shifting focus to a diversified vaccine and therapeutics pipeline amid weak current demand. MRNA guides for up to 10% revenue growth in 2026 but remains deeply loss-making with heavy reliance on future pipeline catalysts and product launches. The recent Phase 3 norovirus vaccine setback highlights execution risk, reinforcing that valuation and sentiment hinge on pipeline progress, not near-term earnings.
Moderna Q2 Earnings Call Highlights
Moderna NASDAQ: MRNA reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range, while continuing to reduce costs and advance programs spanning respiratory vaccines, oncology and rare diseases.
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $1.97 per share in line with the Zacks Consensus Estimate. This compares to a loss of $2.13 per share a year ago.
Moderna Earnings Are Better Than Expected So Why Is the Stock Falling?
The drugmaker's top line continues to be heavily influenced by Covid vaccine sales.
Moderna Q2 Earnings Loom: Buy or Sell the Stock Ahead of Results?
MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.
